| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| - | - | 4,200 | ₹1.5 -61.53% | 500-20% |
| - | - | 4,500 | ₹40 0% | 1250% |
| - | - | 4,700 | - | - |
| - | - | 4,800 | ₹12.05 -33.05% | 1,750600% |
| - | - | 4,900 | ₹22.8 0% | 7500% |
| 6250% | ₹419 0% | 5,000 | ₹26 -6.13% | 8,00042.22% |
| 3750% | ₹432 0% | 5,100 | ₹41.7 0% | 1,6250% |
| 3,00020% | ₹201 -23.09% | 5,200 | ₹62.65 1.37% | 16,25058.53% |
| - | - | 5,250 | ₹85.5 9.61% | 1,875650% |
| 4,375-16.66% | ₹145 -25.41% | 5,300 | ₹103 11.71% | 10,125161.29% |
| - | - | 5,350 | ₹125 13.53% | 3,375107.69% |
| 18,75026.05% | ₹94.5 -29.66% | 5,400 | ₹151.5 8.95% | 14,2500.88% |
| 4,37534.61% | ₹72.2 -33.67% | 5,450 | - | - |
| 36,25072.61% | ₹60.1 -32.05% | 5,500 | ₹208.55 9.87% | 16,6250.75% |
| 5,87567.85% | ₹44.5 -38.74% | 5,550 | ₹222 0% | 2,8750% |
| 5,75027.77% | ₹36 -39.13% | 5,600 | - | - |
| 6,12528.94% | ₹22.8 -34.67% | 5,700 | - | - |
| 2500% | ₹73.7 0% | 5,750 | - | - |
| 20,125168.33% | ₹14 -37.5% | 5,800 | - | - |
| 9,875-17.70% | ₹6.25 -37.5% | 6,000 | - | - |
| 2,500-33.33% | ₹3.35 -55.03% | 6,100 | - | - |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
